Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host confer ...

EGFR D770_N771insNPG (#E10-132GG ... And with longer treatment time of 48 or 72 h, ASK120067, at a low concentration of 0.3 μM, could induced 76.3% or 83.6% more cell apoptosis than DMSO control, and ...

CA$121.4m (up from CA$135.7m loss in FY 2023). Profit margin: 16% (up from net loss in FY 2023). The move to profitability ...